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Bigio et al (1) report that oral administration of acetyl-L-carnitine (ALC) results in antidepressant-like 
effects along with an improvement of energy metabolism in the vDG  in endogenously depressed 
Flinders Sensitive Line rats (FSL). FSL also show a significant reduction of ALC in the hippocampus and 
prefrontal cortex compared to Flinders Resistant Line rats (FRL). However, it is not clear whether such 
deficiency is associated with alterations in the free carnitine concentration, or whether such changes 
in ALC concentrations also occur in other brain regions.  In addition, the study did not show whether 
the ALC-mediated antidepressant effect was linked to a correction of a prior ALC deficiency in these 
two brain regions. Interestingly, only a subset of FSL animals responded to ALC, although both FSL 
responders and non-responders were ALC deficient. It is unclear whether ALC deficiency is pathogenic 
for this mood disorder and/or whether oral administration of ALC corrects a pre-existing deficiency.  
        Orally administered ALC is poorly bioavailable, and is subjected to a fast renal clearance (less than 
10% is reabsorbed). In addition, owing to the presence of carnitine acetyltransferase (CrAT), an 
enzyme catalyzing the transesterification of acetyl-CoA and acetylcarnitine in the mitochondrial 
matrix and peroxisomes, the  C2 moiety in ALC would be efficiently processed by the gut and the liver 
to supplement their respective acetyl-CoA pools, with the release of free carnitine. Therefore, brain 
exposure to ALC is expected to be very low.  Moreover, since ALC also acts as a prodrug of carnitine, it 
would have been appropriate to perform  experiments with FSL animals orally treated with L-
carnitine.   Since it has been shown that ALC may exert pharmacologic effects independently of its 
metabolism (to acetyl-CoA and carnitine), it would be important to exclude a metabolism-
independent effect, e.g. by treating FSL rats with D-acetylcarnitine. 
The authors suggest that ALC-mediated antidepressant action is linked to improved insulin sensitivity 
in FSL animals. Therefore, it would have been instructive to know if treatment with well-established 
insulin-sensitizers (e.g. glitazones)   could have ameliorated mood disorder in the FSL, particularly 
non-responders.   Considering that diabetes significantly raises blood ALC levels, it would be 
anticipated that this condition would also have an antidepressant effect – which can be tested in 
animals, but which is not expected to be borne out in humans, in whom diabetes is frequently 
associated with depression.   
An epigenetic mechanism was proposed for ALC action, implying a pathway leading from extracellular 
ALC to nuclear acetyl-CoA, and acetylation of HRK. This assumes the existence of a nuclear CrAT as 
suggested in (2).  Currently strong evidence for nuclear acetyl-CoA formation comes from 
observations on a nuclear ATP citrate lyase and nuclear pyruvate dehydrogenase complex  (3). 
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